These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 33560720

  • 1. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer.
    Mohamadien NRA, Sayed MHM.
    Nucl Med Commun; 2021 Jun 01; 42(6):656-664. PubMed ID: 33560720
    [Abstract] [Full Text] [Related]

  • 2. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
    Kitao T, Shiga T, Hirata K, Sekizawa M, Takei T, Yamashiro K, Tamaki N.
    Ann Nucl Med; 2019 Jan 01; 33(1):22-31. PubMed ID: 30196378
    [Abstract] [Full Text] [Related]

  • 3. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.
    Qu YH, Long N, Ran C, Sun J.
    Clin Transl Oncol; 2021 Mar 01; 23(3):620-627. PubMed ID: 32683540
    [Abstract] [Full Text] [Related]

  • 4. Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.
    Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, Martínez-González A.
    Mol Imaging Biol; 2017 Aug 01; 19(4):636-644. PubMed ID: 27981471
    [Abstract] [Full Text] [Related]

  • 5. Correlation between 18 F-FDG PET/CT semiquantitative parameters and Ki-67 expression in pulmonary mucosa-associated lymphoid tissue lymphoma.
    Zhao J, Wang H.
    J Med Imaging Radiat Oncol; 2021 Apr 01; 65(2):188-194. PubMed ID: 33538120
    [Abstract] [Full Text] [Related]

  • 6. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep 01; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 7. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B, Zhang Y, Zhou J, Xu Y, Li TR, Ding CY.
    Zhonghua Zhong Liu Za Zhi; 2017 Apr 23; 39(4):280-285. PubMed ID: 28550668
    [Abstract] [Full Text] [Related]

  • 8. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis.
    Arslan E, Can Trabulus D, Mermut Ö, Şavlı TC, Çermik TF.
    J Med Imaging Radiat Oncol; 2021 Feb 23; 65(1):38-45. PubMed ID: 33084216
    [Abstract] [Full Text] [Related]

  • 9. The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer.
    Eryilmaz A, Cengiz A, Basal Y, Meteoglu I, Omurlu IK, Yurekli Y.
    J Cancer Res Ther; 2018 Feb 23; 14(5):994-998. PubMed ID: 30197337
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH, Kang SM, Jeong SY, Lee SW, Lee SJ, Lee J, Ahn BC.
    Clin Nucl Med; 2016 Jun 23; 41(6):e266-73. PubMed ID: 27055144
    [Abstract] [Full Text] [Related]

  • 11. Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study.
    Linguanti F, Abenavoli EM, Briganti V, Danti G, Lavacchi D, Matteini M, Vaggelli L, Novelli L, Grosso AM, Mungai F, Mini E, Antonuzzo L, Miele V, Sciagrà R, Berti V.
    Ann Nucl Med; 2023 Jan 23; 37(1):1-9. PubMed ID: 36309948
    [Abstract] [Full Text] [Related]

  • 12. Relationship between 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters and clinicopathology in endometrial cancer.
    Yao X, Tan X, Zhang H, Yuan H, Zeng B, He L, Jiang L.
    Nucl Med Commun; 2022 Dec 01; 43(12):1233-1238. PubMed ID: 36345768
    [Abstract] [Full Text] [Related]

  • 13. Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer.
    Mayoral M, Paredes P, Saco A, Fusté P, Perlaza P, Tapias A, Fernandez-Martinez A, Vidal L, Ordi J, Pavia J, Martinez-Roman S, Lomeña F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Dec 01; 37(2):80-86. PubMed ID: 28869177
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of FDG-PET and DWI in breast cancer.
    Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K.
    Ann Nucl Med; 2018 Jan 01; 32(1):44-53. PubMed ID: 29134565
    [Abstract] [Full Text] [Related]

  • 15. Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters.
    Ege Aktas G, Taştekin E, Sarikaya A.
    Nucl Med Commun; 2018 Jan 01; 39(1):83-93. PubMed ID: 29135722
    [Abstract] [Full Text] [Related]

  • 16. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.
    Chiacchio S, Evangelista L, Alsharif A, Manca G, DI Martino F, Negri A, Tredici M, Cervino AR, Puccini G, Filidei E, Ghilli M, Naccarato AG, Roncella M, Volterrani D.
    Q J Nucl Med Mol Imaging; 2018 Mar 01; 62(1):101-111. PubMed ID: 26329496
    [Abstract] [Full Text] [Related]

  • 17. Harmonized pretreatment quantitative volume-based 18F-FDG PET/CT parameters for stage IV breast cancer prognosis. Multicenter study in Japan.
    Kitajima K, Miyoshi Y, Sekine T, Takei H, Ito K, Suto A, Kaida H, Daisaki H, Yamakado K.
    Hell J Nucl Med; 2020 Mar 01; 23(3):272-289. PubMed ID: 33367302
    [Abstract] [Full Text] [Related]

  • 18. Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis.
    An YS, Kang DK, Jung Y, Kim TH.
    Medicine (Baltimore); 2017 Nov 01; 96(45):e8557. PubMed ID: 29137072
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients.
    Tosi D, Pieropan S, Cattoni M, Bonitta G, Franzi S, Mendogni P, Imperatori A, Rotolo N, Castellani M, Cuzzocrea M, Schiorlin I, Casagrande S, De Palma D, Nosotti M, Dominioni L.
    Clin Nucl Med; 2021 Aug 01; 46(8):621-626. PubMed ID: 34034316
    [Abstract] [Full Text] [Related]

  • 20. Characterization of sacral chordoma and differential diagnosis from other sacral malignancy using [18F]FDG PET/CT.
    Lee DY, Kim YI, Ryu JS, Kim W.
    Medicine (Baltimore); 2024 Apr 05; 103(14):e37678. PubMed ID: 38579025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.